go to contents

BioNTech R&D (Austria) GmbH

Back to list

Facts

Founded
2017
Staff
20
Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health

Profile

BioNTech R&D Austria, a wholly owned subsidiary of BioNTech SE since October 2021, is a research hub within the BioNTech Group specializing in the development of new anti-bacterial agents. At the site in Vienna, Austria, a team of approximately 20 scientists research and develop precision therapies against bacterial infections.

R&D:The research hub resulted from the acquisition of PhagoMed, a Viennese biotech that has been developing pathogen-specific lysin-based antimicrobials since 2018. The core of the technology platform is the LysinBuilder™, a platform for in-silico prediction and pharmaceutical development of synthetic lysins. Lysins are proteins that specifically cut the cell wall of individual bacterial genera, killing the bacterial cells.

Similar companies in RDM biotech/pharma

3D Spine Matrix Biotechnologie GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Focus
human health
Details

Orpha Trade GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Cluster
LISAvienna
Focus
human health
Details

Tridem Bioscience GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Focus
human health
Details

ENSEMO GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Details

Contact

Leberstraße 20
1110 Wien
Vienna

Contact: Alexander Belcredi (Co-Founder | CEO)
Email: contact@phagomed.com
Website